KR20100051797A - 안정화된 피코플라틴 투여형 - Google Patents

안정화된 피코플라틴 투여형 Download PDF

Info

Publication number
KR20100051797A
KR20100051797A KR1020107001745A KR20107001745A KR20100051797A KR 20100051797 A KR20100051797 A KR 20100051797A KR 1020107001745 A KR1020107001745 A KR 1020107001745A KR 20107001745 A KR20107001745 A KR 20107001745A KR 20100051797 A KR20100051797 A KR 20100051797A
Authority
KR
South Korea
Prior art keywords
cancer
picoplatin
dosage form
solution
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107001745A
Other languages
English (en)
Korean (ko)
Inventor
알리스테어 제이. 레이
크리스토퍼 에이. 프로시신
로날드 에이. 마르텔
데이비드 에이. 카린
체니 궉
Original Assignee
포니아드 파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포니아드 파마슈티칼즈, 인크. filed Critical 포니아드 파마슈티칼즈, 인크.
Publication of KR20100051797A publication Critical patent/KR20100051797A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020107001745A 2007-06-27 2008-06-27 안정화된 피코플라틴 투여형 Withdrawn KR20100051797A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US94663907P 2007-06-27 2007-06-27
US60/946,639 2007-06-27
US2738808P 2008-02-08 2008-02-08
US61/027,388 2008-02-08
US5507108P 2008-05-21 2008-05-21
US61/055,071 2008-05-21

Publications (1)

Publication Number Publication Date
KR20100051797A true KR20100051797A (ko) 2010-05-18

Family

ID=40429589

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107001745A Withdrawn KR20100051797A (ko) 2007-06-27 2008-06-27 안정화된 피코플라틴 투여형

Country Status (12)

Country Link
US (2) US20100215727A1 (enExample)
EP (1) EP2157864A4 (enExample)
JP (1) JP2010531877A (enExample)
KR (1) KR20100051797A (enExample)
CN (1) CN101801198A (enExample)
AU (1) AU2008295576A1 (enExample)
BR (1) BRPI0811816A2 (enExample)
CA (1) CA2691115A1 (enExample)
IL (2) IL202743A0 (enExample)
MX (1) MX2009013835A (enExample)
TW (1) TW200916094A (enExample)
WO (1) WO2009032034A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
WO2010132596A1 (en) * 2009-05-12 2010-11-18 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
KR20090109130A (ko) * 2007-02-09 2009-10-19 포니아드 파마슈티칼즈, 인크. 캡슐화된 피코플라틴
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
EP2249827A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc USE OF PICOPLATIN AND CETUXIMAB IN THE TREATMENT OF COLORECTAL CANCER
WO2010120336A1 (en) * 2009-04-15 2010-10-21 Poniard Pharmaceuticals, Inc. High bioavailability oral picoplatin anti-cancer therapy
CN101804025B (zh) * 2010-03-31 2011-09-21 昆明贵研药业有限公司 甲啶铂的一种水溶液注射剂
CN102590385B (zh) * 2012-02-14 2013-09-11 昆明贵研药业有限公司 一种甲啶铂及其杂质的检测方法
EP3294292A1 (en) * 2015-05-13 2018-03-21 Monopar Therapeutics Inc. Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
PT3393478T (pt) * 2015-12-23 2020-03-24 NuCana plc Terapia combinada
CN106943343B (zh) * 2016-01-06 2020-05-12 山东新时代药业有限公司 一种甲啶铂注射液及其制备方法
CN107773538B (zh) * 2016-08-27 2022-09-13 鲁南制药集团股份有限公司 稳定的甲啶铂无菌冻干粉末及其制备工艺
WO2023207931A1 (zh) * 2022-04-26 2023-11-02 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1432562A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
GB2060615B (en) * 1979-08-23 1983-06-22 Johnson Matthey Co Ltd Platinum-amine complexes
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
GR75317B (enExample) * 1980-09-03 1984-07-13 Johnson Matthey Plc
US4533502A (en) * 1983-02-22 1985-08-06 Rochon Fernande D Platinum (II) compounds and their preparation
ATE63919T1 (de) * 1984-06-27 1991-06-15 Johnson Matthey Plc Platinkoordinationsverbindungen.
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
CA1327039C (en) * 1986-12-18 1994-02-15 Tetsushi Totani Ammine-alicyclic amine-platinum complexes and antitumor agents
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB9105037D0 (en) * 1991-03-09 1991-04-24 Johnson Matthey Plc Improvements in chemical compounds
US5244991A (en) * 1991-10-15 1993-09-14 Phillips Petroleum Company Olefin polymerization process
AU671605B2 (en) * 1991-11-15 1996-09-05 Smithkline Beecham Corporation Combination chemotherapy
EP0672181B1 (en) * 1992-04-01 2003-11-05 The Johns Hopkins University School Of Medicine Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor
FI955979L (fi) * 1993-06-14 1995-12-13 Janssen Pharmaceutica Nv Jatkuvasti vapauttava, kalvopäällysteinen astemitsoli- ja pseudoefedriinitabletti
US5624919A (en) * 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
GB9408218D0 (en) * 1994-04-26 1994-06-15 Johnson Matthey Plc Improvements in platinum complexes
AU2768295A (en) * 1994-07-11 1996-02-09 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
CA2258956A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
ES2208946T3 (es) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
DE19847618A1 (de) * 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6235782B1 (en) * 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
US6413953B1 (en) * 1999-04-13 2002-07-02 Anormed Inc. Pt(IV) antitumor agent
SK286374B6 (sk) * 1999-04-13 2008-08-05 Anormed Inc. Spôsob prípravy cis-komplexu platiny a cis-komplex platiny
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
RU2002124599A (ru) * 2000-02-16 2004-03-10 Яманоути Фармасьютикал Ко., Лтд. (JP) Фармацевтическая композиция
CA2397657A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica Inc. Farnesyl protein transferase inhibitor combinations with platinum compounds
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US20020110601A1 (en) * 2000-03-31 2002-08-15 Roman Perez-Soler Antineoplastic platinum therapeutic method and composition
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US6806289B1 (en) * 2000-07-14 2004-10-19 Stephen J. Lippard Coordination complexes, and methods for preparing by combinatorial methods, assaying and using the same
AU2001277711A1 (en) * 2000-08-11 2002-02-25 Sumitomo Pharmaceuticals Co. Ltd. Remedies for cisplatin-tolerant cancer
US6894049B1 (en) * 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
US6544962B1 (en) * 2000-11-02 2003-04-08 Matrix Pharmaceutical, Inc. Methods for treating cellular proliferative disorders
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US6673370B2 (en) * 2001-05-15 2004-01-06 Biomedicines, Inc. Oxidized collagen formulations for use with non-compatible pharmaceutical agents
DK1416917T3 (da) * 2001-08-06 2007-09-17 Astrazeneca Ab Vandig dispersion, der omfatter stabile nanopartikler af et vanduoplöseligt aktivt stof og en excipiens som middellangkædede triglycerider (MCT)
WO2003015778A1 (en) * 2001-08-17 2003-02-27 Merck & Co., Inc. Tyrosine kinase inhibitors
US20030059375A1 (en) * 2001-08-20 2003-03-27 Transave, Inc. Method for treating lung cancers
DE10141528B4 (de) * 2001-08-24 2006-08-10 Faustus Forschungs Cie. Translational Cancer Research Gmbh Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
WO2003057128A2 (en) * 2001-12-11 2003-07-17 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
US20050119238A1 (en) * 2002-03-01 2005-06-02 Baron John A. Compositions and methods for preventing sporadic neoplasia in colon
US20040010553A1 (en) * 2002-07-15 2004-01-15 International Business Machines Corporation Peer to peer location based services
US7038071B2 (en) * 2002-07-16 2006-05-02 Sonus Pharmaceuticals, Inc. Platinum compounds
WO2004012680A2 (en) * 2002-08-06 2004-02-12 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
US8217010B2 (en) * 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE10256182A1 (de) * 2002-12-02 2004-06-24 Merck Patent Gmbh 2-Oxadiazolchromonderivate
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1473293B1 (de) * 2003-04-30 2008-03-19 MERCK PATENT GmbH Chromenonderivate
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
JP2007537235A (ja) * 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療用ピリミジン誘導体
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CA2584493A1 (en) * 2004-06-18 2006-01-05 Gpc Biotech, Inc. Kinase inhibitors for treating cancers
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1793830A2 (en) * 2004-09-22 2007-06-13 Pfizer, Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US7807662B2 (en) * 2004-12-23 2010-10-05 University Of South Florida Platinum IV complex inhibitor
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
WO2006104668A2 (en) * 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
CA2606147C (en) * 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters
CA2620389C (en) * 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US20070190181A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
CN101442998B (zh) * 2006-03-16 2012-03-14 比奥纽默里克药物公司 抗癌活性加强化合物和制剂及其用法
WO2007147265A1 (en) * 2006-06-23 2007-12-27 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
BRPI0720850A2 (pt) * 2006-12-20 2013-01-29 J C Health Care Ltd mÉtodo para administraÇço de doxorrubicina lipossomal peguilada
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
KR20090109130A (ko) * 2007-02-09 2009-10-19 포니아드 파마슈티칼즈, 인크. 캡슐화된 피코플라틴
US7687487B2 (en) * 2007-04-19 2010-03-30 Bionumerik Pharmaceuticals, Inc. Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same
EP2152076A4 (en) * 2007-05-31 2011-02-16 Ascenta Therapeutics Inc PULSATIVE DOSE OF GOSSYPOL FOR THE TREATMENT OF A DISEASE
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
JP5410434B2 (ja) * 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
EP2249827A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc USE OF PICOPLATIN AND CETUXIMAB IN THE TREATMENT OF COLORECTAL CANCER

Also Published As

Publication number Publication date
AU2008295576A1 (en) 2009-03-12
EP2157864A4 (en) 2013-09-11
US20100215727A1 (en) 2010-08-26
IL251175A0 (en) 2017-04-30
IL202743A0 (en) 2010-06-30
WO2009032034A3 (en) 2009-04-30
CA2691115A1 (en) 2009-03-12
JP2010531877A (ja) 2010-09-30
WO2009032034A2 (en) 2009-03-12
EP2157864A2 (en) 2010-03-03
US20100178328A1 (en) 2010-07-15
BRPI0811816A2 (pt) 2014-12-30
CN101801198A (zh) 2010-08-11
TW200916094A (en) 2009-04-16
MX2009013835A (es) 2010-05-17

Similar Documents

Publication Publication Date Title
KR20100051797A (ko) 안정화된 피코플라틴 투여형
RU2207857C2 (ru) Лекарственный препарат оксалиплатина в виде стабильного водного раствора, способ его получения и применение
JP2010531877A5 (enExample)
JP2011511072A (ja) 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用
JP2020183416A (ja) 疾患の治療方法
US20100062056A1 (en) Encapsulated picoplatin
WO2011089234A2 (en) Method and composition
ES2968415T3 (es) Sistema de perfusión
JP2025163103A (ja) 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
US20100260832A1 (en) Combination therapy for ovarian cancer
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
KR101851820B1 (ko) 치료적 요법
ES2774101T3 (es) Cabazitaxel y su uso para tratar cáncer
CA3223395C (en) Use of adenosine diphosphate ribose as adjuvant therapy for radiation and/or anticancer therapy
WO2019220961A1 (ja) ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤
CN107456456A (zh) 伊立替康或其可药用盐在制备治疗乳腺癌的药物中的用途
CN115463143A (zh) 非天然人参皂苷3β,12β-Di-O-Glc-PPD治疗脑瘤的用途
Goldenberg Chemotherapy Foundation Symposium XXVI: Innovative Cancer Therapy for Tomorrow
RU2010102096A (ru) Стабилизированная лекарственная форма пикоплатина и ее применение
HK1236852A1 (en) Aqueous solution comprising 3-quinuclidinone derivative for the treatment of hyperproliferative diseases, autoimmune diseases and heart diseases
HK1155089A (en) Use of picoplatin and bevacizumab to treat colorectal cancer
NZ616410B2 (en) Combination treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100126

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid